Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

Nightstar Therapeutics
Posted on: 02 Oct 17

LEXINGTON, Mass. and LONDON, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar" or the "Company") (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the closing of its previously announced initial public offering in the United States of 6,164,000 American Depositary Shares ("ADSs") representing 6,164,000 ordinary shares, at an initial public offering price of $14.00, which includes an additional 804,000 ADSs issued upon the exercise in full by the underwriters of their option to purchase additional ADSs.  Aggregate net proceeds to the Company, after underwriting discounts and commissions and estimated offering expenses payable by the Company, will be approximately $76.9 million. All of the ADSs were offered by Nightstar.

Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. acted as joint book-running managers for the offering. Wedbush Securities Inc. and Chardan acted as co-managers.

The offering was made only by means of a prospectus.  A copy of the prospectus relating to the offering was filed with the U.S. Securities and Exchange Commission and may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by email at; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6132, or by email at; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, or by telephone at (800) 414-3627, or by email at

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission.  This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About Nightstar

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy.


Senthil Sundaram, Chief Financial Officer  

Alicia Davis, THRUST IR

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Nightstar Therapeutics via GlobeNewswire

Last updated on: 03/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.